Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Amgen Is Proving It Is Still the Biotech King. Nektar Forms a Subsidiary Firm to Market Its Pain Product NKTR-181, When Approved

May 24, 2019 0

Amgen, the Biotech King Amgen (AMGN), the biotech king, wanted to buy all of the Denmark …

Vertex: Good News and Good Decisions

May 23, 2019 0

Vertex’s Good News Vertex and Kymera Therapeutics Collaboration Last week Vertex Pharmaceuticals (VRTX) and Kymera Therapeutics entered …

Array BioPharma: Great News and a Learning Experience

May 21, 2019 0

Great News for Array BioPharma Array BioPharma (ARRY) announced positive results from the interim analysis of …

The Medicines Company: Are Inclisiran’s Clinical Trial Results Impressive?

May 21, 2019 0

The Medicines Company Are Inclisiran's Clinical Trial Results Impressive? Our answer is YES. The trial results …

Another Late-Stage Firm with Impressive Technology and Promising Products

May 16, 2019 0

About Iovance Biotherapeutics Iovance Biotherapeutics (IOVA) is a late-stage biotechnology company developing novel cancer immunotherapies based on …

Advaxis: Why This Small Firm’s Stock Outperformed on a Negative Market Day

May 15, 2019 0

Advaxis Outperformed on a Negative Market Day ADXS Outperformed Advaxis’ (ADXS) stock rallied today as the …

Regeneron: Why the FDA Approval of EYLEA for Diabetic Retinopathy is Extremely Important.

May 14, 2019 0

The FDA Approval of Regeneron's EYLEA Is Important The PANORAMA Trial of EYLEA for Diabetic Retinopathy …

Exelixis’ and Daiichi Sankyo’s Novel Antihypertensive Drug Minnebro® Hits the Japanese Market

May 13, 2019 0

Exelixis and Daiichi Sankyo launched their novel anitihypertension product Minnebro® in Japan Exelixis (EXEL) and Daiichi Sankyo (

Will the Bear Escape Tonight from the Market? Regeneron and Severe Asthma Patients Good News

May 9, 2019 0

The Stock Market The Confused and Confusing Stock Market The stock market is confused and confusing. …

A Firm That Defied the Fierce Unwarranted Bear Market Day

May 7, 2019 0

Why GW Pharmaceuticals Survived the Bear Market Day The DOW Today Sinking for disputed and unfathomed …

Bluebird bio and Celgene: Encouraging Clinical Trial Results for Last Resort Multiple Myeloma Treatment

May 3, 2019 0

A Great Day for Bluebird bio and Celgene Read the Clinical Trial Results for Myeloma What …

Vertex Has Good News and Exelixis Is Reinforcing Its Outperformance

May 2, 2019 0

Vertex Pharmaceuticals' Product Kalydeco for CF in Young Children Good news for Vertex (VRTX) product Kalydeco® (ivacaftor) is …

The FDA Approval of Regeneron/Sanofi Praluent Is A Big Deal. Will the FDA Approve Nabriva Therapeutics’ Antibiotic Contepo Today?

April 30, 2019 0

Praluent's Approval Is a Big Deal The approval of the Regeneron / Sanofi supplemental biological license …

Trick or Trade?

April 26, 2019 0

The Misleading Market? The biotech stocks continue to begin their daily trading relying on opinionated articles …

Exelixis and Aerie Have Good News

April 25, 2019 0

Exelixis & Aerie Have Good News Exelixis’ Good News about Cabometyx Takeda Pharmaceuticals applied to the …

Trovagene’s News Is Encouraging

April 24, 2019 0

About Trovagene Trovagene (TROV) is still a clinical-stage company. The precision cancer medicine approach is practicing what …

Novartis Gene Therapy Zolgensma Will Be Approved. The FDA Approves a Merck Combination for First-Line Renal cell Carcinoma. Regenxbio and Exelixis Are in Great Shape.

April 22, 2019 0

Zolgensma Findings The FDA submission of the gene therapy product Zolgensma was based on positive findings …

Novartis: More promising data from a Phase 3 trial with AveXis’ gene therapy Zolgensma® for Spinal Muscular Atrophy Type 1

April 17, 2019 0

Novartis Has More Promising Data from Their Phase 3 Gene Therapy Trial with AveXis AveXis Inc., …

Gilead and insitro announce strategic collaboration to discover and develop novel therapies for NASH

April 16, 2019 0

Gilead and insitro Collaborate to Discover and Develop Novel Therapies for NASH using ISH Gilead Sciences …

The Week in Review #40

April 16, 2019 0

Conquering NASH Gilead and Novo Nordisk Conquering NASH What was Gilead Sciences' (GILD) announcement at …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Amgen Is Proving It Is Still the Biotech King. Nektar Forms a Subsidiary Firm to Market Its Pain Product NKTR-181, When Approved

Vertex: Good News and Good Decisions

Array BioPharma: Great News and a Learning Experience

The Medicines Company: Are Inclisiran’s Clinical Trial Results Impressive?

Another Late-Stage Firm with Impressive Technology and Promising Products

Advaxis: Why This Small Firm’s Stock Outperformed on a Negative Market Day

Regeneron: Why the FDA Approval of EYLEA for Diabetic Retinopathy is Extremely Important.

Exelixis’ and Daiichi Sankyo’s Novel Antihypertensive Drug Minnebro® Hits the Japanese Market

Will the Bear Escape Tonight from the Market? Regeneron and Severe Asthma Patients Good News

A Firm That Defied the Fierce Unwarranted Bear Market Day

Bluebird bio and Celgene: Encouraging Clinical Trial Results for Last Resort Multiple Myeloma Treatment

Vertex Has Good News and Exelixis Is Reinforcing Its Outperformance

The FDA Approval of Regeneron/Sanofi Praluent Is A Big Deal. Will the FDA Approve Nabriva Therapeutics’ Antibiotic Contepo Today?

Trick or Trade?

Exelixis and Aerie Have Good News

Trovagene’s News Is Encouraging

Novartis Gene Therapy Zolgensma Will Be Approved. The FDA Approves a Merck Combination for First-Line Renal cell Carcinoma. Regenxbio and Exelixis Are in Great Shape.

Novartis: More promising data from a Phase 3 trial with AveXis’ gene therapy Zolgensma® for Spinal Muscular Atrophy Type 1

Gilead and insitro announce strategic collaboration to discover and develop novel therapies for NASH

The Week in Review #40